| 前收市價 | 15.16 |
| 開市 | 15.23 |
| 買盤 | 15.01 x 100 |
| 賣出價 | 15.62 x 100 |
| 今日波幅 | 14.90 - 15.52 |
| 52 週波幅 | 4.60 - 20.90 |
| 成交量 | |
| 平均成交量 | 399,159 |
| 市值 | 679.346M |
| Beta 值 (5 年，每月) | 0.76 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.49 |
| 業績公佈日 | 2024年5月06日 - 2024年5月10日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 21.43 |
ZacksWall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 31.3% in YmAbs Therapeutics (YMAB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ZacksYmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
ZacksWall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
The consensus price target hints at a 31.4% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
